Cidara Therapeutics announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock. The closing of each proposed offering is not contingent upon the closing of the other. Cantor Fitzgerald & Co. is acting as the sole book-running manager for each offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDTX:
- Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
- Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
- Cidara Therapeutics announces interim Phase 2a data of CD388
- Cidara regains compliance with Nasdaq minimum bid price requirement
- Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement